DBT-50201 / Diverse Biotech - LARVOL DELTA

Diverse Biotech Announces New Patent Approval for Its PEMBROLIZUMAB Antibody Drug DBT-50201 (Businesswire) - "Diverse Biotech has been granted USPTO patent approval of its novel CUSP synthesis platform creating an entirely new class of drugs that are part-antibody and part-cannabinoid in one new molecule. Starting with DBT-50201, its novel PEMBROLIZUMAB compound, Diverse expects to develop multiple treatments for many diseases with highly unmet needs....We expect that our monoclonal drug DBT-50201 will mirror the results we have seen thus far in trials with our Temozolomide drug used to treat Glioblastomas (brain cancer), DBT-30180."

Patent • Brain Cancer • CNS Tumor • Glioblastoma • Oncology